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Oxygen homeostasis under conditions of limited O2 supply requires hypoxia-dependent gene regulation. The transcription factor complex
hypoxia-inducible factor 1 (HIF-1) has been recognized as the master regulator that mediates the adaptational genetic response to ensure
restoration of energy supply. This review will focus on the recent advances in understanding the hypoxia-induced cellular response with
particular respect to cellular O2 sensing for adequate control of HIF-1 activation.
© 2006 European Society of Cardiology. Published by Elsevier B.V. All rights reserved.Keywords: HIF-1; Hypoxia; Hypoxia-induced gene expression1. O2 sensing via HIFα factors
Crucial to linking reduced oxygen supply to changes in
gene expression are hypoxia-inducible transcription factors,
or HIFs [1]. Across the animal kingdom, HIF is a
heterodimer of α- and β subunits. Both subunits belong to
the family of basic-helix-loop-helix (bHLH)/PAS1 transcrip-
tion factors. Under physiological oxygen partial pressures
(pO2), HIF is quickly destabilized. In contrast, α and β
subunits heterodimerize in the nucleus in response to oxygen
deprivation. Here, the dimer specifically binds to target gene
motifs called hypoxia response elements (HREs) to either
induce or suppress gene expression. A decade after the
seminal identification of HIF-1 as the responsible factor for
the hypoxia-induced transcription of the red cell producing
hormone erythropoietin [2], this transcription factor has now
been implicated to possibly control even up to several
hundreds (i.e. ∼2–5% of genome) of hypoxia-responsive⁎ Corresponding author. Tel./fax: +49 201 723 4600/4648.
E-mail address: joachim.fandrey@uni-due.de (J. Fandrey).
1 PAS: acronym for PER, ARNT, SIM, the first proteins discovered to
contain this domain.
0008-6363/$ - see front matter © 2006 European Society of Cardiology. Publish
doi:10.1016/j.cardiores.2006.05.005genes in humans [3]. In mammals, the 70 HIF targets
validated to date [4] typically fall into two main categories
whose functions aim to restore energy and O2 homeostasis
by either cell-autonomous or systemic means:
(a) increasing anaerobic energy production via stimulated
glycolytic substrate flux;
(b) improving tissue oxygenation via stimulated angio-
genesis, vasodilation and erythropoiesis.
HIF signaling – although not the only pathway linking
declining pO2 with changes in DNA activity (see Cummins
and Taylor [5] for a recent review on HIF-independent
transcription responses to hypoxia) – has thus been
appreciated as a major component in the homeostatic
adaptations and survival of cells under both physiological
and tumorigenic-pathological oxygen limitations [6]. Not-
withstanding this key importance for hypoxic survival, the
mechanisms and players behind this switch from active
(hypoxia) to inactive (normoxia, reoxygenation) states of
HIF signaling were only poorly understood until recently.
Fortunately, there has been a remarkable progress made
during the last 5 years, advancing our comprehension ofed by Elsevier B.V. All rights reserved.
Fig. 1. HIF-α mediated pathway of O2 sensing. Molecules are not drawn to scale. Prolyl hydroxylase in the figure represents PHD1–3. For further details see text. 643
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this recent progress, with a particular focus on the
hydroxylase-mediated regulation of the HIF signaling
pathway, is the goal of this current review.
From nematodes to crustaceans to flies to vertebrates, HIF
activity is controlled at the protein level through oxidative
modifications of the α subunits [7]. Multiple isoforms of
these regulatory HIF proteins exist in fish, amphibians, birds
and mammals [8]. Three HIF-α subunits (HIF-1α, -2α and
-3α) have been reported in human and rodent cells, with five
and six splice variant transcripts known to occur for the
human 1α and 3α isoforms, respectively [9,10]. All three α
subunit factors share the ability to heterodimerize with the
ubiquitously expressed HIF-1β subunit, originally known as
the aryl hydrocarbon receptor nuclear translocator or ARNT,
thus producing HIF-1, -2 and -3. While both stability and
activity of the 1α, 2α and some 3α (i.e. 3α1–3α3) subunits
are quickly impaired by normoxia or reoxygenation, the
steady state levels of the ARNT protein are unaffected by
changes in oxygen tension [11]. As outlined in detail below,
and summarized in Fig. 1, the HIF oxygen sensors, that
control the abundance of HIF-α proteins in the cell are a
family of novel prolyl hydroxylases named PHD1-3, for the
characteristic prolyl hydroxylase domains contained within
the reading frame [12–14]. In the presence of oxygen, these
PHDs catalyze the Fe(II)-dependent hydroxylation of
specific prolyl residues (Pro402 and Pro564 in human HIF-
1α) contained within the oxygen-dependent degradation
domain (ODD) of HIF-1α [15], -2α or -3α1–3 subunits (see
Fig. 1: ODD hydroxy-prolines as “OH”). Once hydroxylat-
ed, the HIF-α subunits rapidly bind to the von Hippel-Lindau
(pVHL) tumor suppressor protein that is the recognition
component of an E3 ubiquitin ligase complex, thereby tying
prolyl hydroxylation to ubiquitination and proteasomal
degradation of these regulatory constituents under high or
rising pO2 (e.g. [16,17]; see Fig. 1). In addition, acetylation
of ODD-contained lysines (e.g. K532 in human HIF-1α) via
acetyltransferases such as ARD1 might be another, though
currently far more controversially discussed, enzymatic
trigger for enhanced pVHL recognition and destabilization
of alpha subunits [18–20]. Unlike PHDs, the activity of
acetyltransferases is not known to be influenced by changes
in oxygen tension, thus making it hard to see how normoxia
should lead to differentially high rates of protein substrate
acetylations (for review see [21,22]). Notwithstanding our
incomplete mechanistic understanding, the efficacy of these
hydroxylation- (and potentially acetylation-) based post-
translational controls can best be appreciated by the <5 min
half-life of HIF-1α upon reoxygenation [11] and, conversely,
the instantaneous accumulation of the transcription factor in
vitro [23] and in vivo [24] during declining oxygen tensions.
A second O2-requiring hydroxylation, that of a single
asparagine (Asn803 in human HIF-1α) within the C-terminal
transactivation domain of HIF-1α and -2α (see Fig. 1: TAD-
C, hydroxyl-asparagine as “OH”) by an asparaginyl
hydroxylase dubbed FIH-1 (factor inhibiting HIF-1), leadsto steric hindrance of the interaction between α subunits and
the coactivator proteins p300/CBP (note: lack of TAD-C
domains in 3α isoforms). This hindrance prohibits the
transactivation of target genes under high pO2 [25,26]. The
absolute requirement of PHD- and FIH-1 activities for
oxygen and Fe2+ [27–29] has made these hydroxylation
reactions susceptible to inhibition not only by declining pO2
but also by hypoxia-mimicking agents such as transition
metals (e.g., Co2+) and iron chelators (e.g., desferrioxamine,
DFO; ciclopiroxolamine (CPX) [12,30]). Long before the
discovery of PHD-mediated O2 sensing, Co
2+, DFO and
CPX were empirically known to be able to induce
erythropoietin, i.e. HIF target, gene responses under
normoxia [31,32]. As a strength of concept, insights into
the catalytic requirements of PHDs can now incorporate
these earlier data into a plausible model of HIF control. Upon
exposure to hypoxia, cobalt or iron chelators, hydroxylation
of prolyl and asparaginyl residues is reduced (see Fig. 1).
This inhibition enables the α subunit to escape proteolytic
degradation and, assisted by various interacting factors (e.g.
heat shock protein 90, HSP 90) [4,33] and/or stimulatory
kinase signals (reviewed in [6]), to efficiently translocate into
the nucleus where the phosphorylated form (P) dimerizes
with ARNT (reviewed in [22]) through intermolecular
interactions between the HLH and PAS domains (see Fig.
1). Next, the α:β heterodimer associates with the transcrip-
tional coactivators p300/CBP and Src-1 to regulate target
gene transcription via HRE binding sites. Specific recogni-
tion of HRE motifs is accomplished through the N-terminal
basic (b) region in both factors (see Fig. 1: 5′TACGTG3′
given as HRE example; note: α subunit occupancy of 5′ TAC
nucleotides, and β subunit binding to 3′ GTG nucleotides).
The HIF/coactivator complex is now endowed to modulate
the activity of the general transcription factor (GTF)/RNA
polymerase II machinery in a hypoxia-responsive fashion.
2. Regulation of HIFα by hydroxylation
As mentioned above, both the regulation of O2-dependent
lability and thus protein abundance as well as transcriptional
activity of HIF-α subunits depend on hydroxylation. So far,
PHD1, PHD2, PHD3 and FIH-1 have been identified to
perform this post-translational modification. They now
appear as today's best candidates for cellular HIF oxygen
sensors. A fourth prolyl hydroxylase termed PH-4 has been
isolated from a database approach [34]. Although this
protein showed great similarity to the known PHDs and was
able to suppress HIF-accumulation and HIF-dependent
reporter gene activation, it failed to show activity in an
HIF-1α-pVHL in vitro interaction assay. Therefore the role
as an HIF prolyl hydroxylase, particularly with O2 dependent
activity, is currently not clear.
Initially, the search for HIF-associated O2 sensors focused
on heme proteins that would – in response to altered states in
oxygenation – change their heme conformation and valency
and thereby generate a signal to control O2-dependent gene
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ylation of HIF-α implied O2-dependent enzymatic activity.
Subsequently, it was demonstrated that modification of
proline residues in the ODD of HIF-α controls abundance
while asparagine hydroxylation is the important switch for
regulating the binding of coactivator p300/CBP [17,35].
Conservation of the O2-sensing system down to C. elegans
helped to define a new family of dioxygenases that regulate
HIF-α by prolyl hydroxylation [12,13,36]. Although the
human homologues were variously named HPH-1/EGLN3/
PHD3, HPH-2/EGLN1/PHD2, and HPH-3/EGLN2/PHD1
[37] we will use the initial term PHD1, -2, and -3. Shortly
thereafter the enzyme hydroxylating the TAD-C previously
termed FIH-1 was identified as an asparaginyl hydroxylase
that fell into the same family of dioxygenases [26].
By definition, dioxygenases metabolize molecular oxy-
gen and incorporate both atoms of oxygen into their
products. PHDs and FIH-1 are Fe2+, 2-oxoglutarate (2OG)
and ascorbate dependent non-heme binding oxygenases of
which the enzymatic activity is regulated by O2 availability
(see Fig. 1). With respect to cellular localization and O2
regulated enzymatic activity they differ from the well-known
collagen prolyl hydroxylase (C-P4H1) whose α(I) subunit is
a HIF-1 target gene [38]. Like PHDs and FIH-1, the C-P4H1
releases CO2 and succinate upon completion of the
enzymatic cycle and its activity depends on substrate and
ascorbate concentration as it is well known from scurvy.
However, the most significant difference related to their
function was found when the affinity for O2 was determined
for the PHDs and FIH-1 and compared to C-4PH1. While the
Km value for O2 of the C-P4H1 was around 40 μM, values
initially reported for the PHDs were between 230 and
250 μM which exceeds even the concentration of O2 in air
[39]. For FIH-1, the Km was found to be considerably lower,
90 μM [40], but still more than twice as high as that of C-
P4H1 (40 μM; [41]). These Km values were determined
using the 14CO2 release from labeled 2OG catalyzed by
recombinant enzymes and short 19 amino acid (aa) HIF-α
peptides as substrates. A caveat with respect to these Km
measurements has been expressed since interpretation of the
O2 affinity would need to consider the reaction kinetics of
the enzymes [42]. In general, information on the kinetics of
prolyl hydroxylases is mainly based on data from C4-PH1,
but not from PHDs. In C4-PH1, O2 appears to be bound first
to the enzymatic complex. Subsequently, the enzyme–O2
complex is stabilized by binding pro-collagen polypeptide
substrate [43]. More recently, this order of binding was
questioned. Instead, it was proposed that a preformed
enzyme–substrate complex binds O2 [44], which would be
in line with crystallography data on FIH-1, where such a
preformed enzyme–Fe2+–2OG–substrate complex was de-
scribed to bind O2 [45]. This order of binding implies,
however, that substrate bound to the enzyme could affect the
Km for O2. Indeed, when the length of HIF-α peptides used
for in vitro assays was extended to 200 aa the Km value for
O2 of the PHDs dropped to 100 μM (Johanna Myllyharju,personal communication, 2006). Whether full length HIF-α
proteins would lower the Km even further is still a matter of
debate. Full length HIF-α proteins are almost insoluble and
have not been used in the in vitro enzymatic measurements.
Even a Km of 100 μM corresponds with the maximal O2
concentrations in the body, the alveolar pO2 in the lung.
Oxygen tensions in the tissue, particularly in the kidney
where HIF signaling is required for erythropoietin expres-
sion [46], or in the placenta where HIF is required for regular
development [47], are certainly lower than any of the Km
values determined so far. Measurement of tissue pO2 under
physiological conditions has been notoriously difficult. Most
of the technical pO2 sensors, e.g. of Clark-type, consume
oxygen and thus blur measurements of pO2. In addition,
tissue pO2 is determined by the ratio of the rate of
consumption to the rate of supply which may vary even
within tissue areas very close to each other [48]. However, a
range of oxygen concentration from 40 down to 4 μM may
reasonably be assumed. As such, the high Km for oxygen
would place the steep slope range of the activity curve
determined for PHDs and FIH-1 right into the range of
physiological pO2 values. Any incremental reduction in the
pO2 would thus trigger a marked lowering of hydroxylation
capacity [42]. This was demonstrated already in the first
description of PHDs when a decrease in HIF hydroxylation
between pO2 values of 150 mm Hg and 75 mm Hg was
found [12]. Interestingly, the Km of FIH-1 is lower than for
PHDs and indeed, experiments indicate that FIH-1 control
dominates HIF activation during exposures to a lower pO2
range [49]. The emerging picture of graded hydroxylase
activities that operate with maximal sensitivity in the range
of physiological tissue pO2 thus fits initial in vitro
observations, where half-maximal activation of HIF signal-
ing was reported at oxygen concentrations of 15 to 20 μM
[50]. Detection of nuclear HIF-1α in cells, under conditions
where the pericellular pO2 was measured and oxygen
consumption was taken into account [51], indicates that
HIF accumulation may be achieved at higher pO2 values but
that, in addition, cell-specific differences may exist [52].
Collectively, however, there is no doubt that the absolute
requirement for O2 causes lack of enzymatic activity under
anoxia. Upon a graded decrease of the pO2 within the
physiological range overall hydroxylation capacity of PHDs
and FIH-1 will become limiting and thus the overall process
of hydroxylation will be rate-limiting in the system that
regulates HIF abundance and activity. As such, the enzymes
fulfill the criteria of oxygen sensors. In addition, the pO2
range in which the oxygen sensors work may be affected by
abundance of the enzymes themselves [42]. This would, in
fact, explain different oxygen sensitivity for cells in culture
under identical physical conditions [52].
3. Hydroxylase abundance and interacting proteins
Prolyl- and asparaginyl-hydroxylases are non-equilibrium
enzymes because they only catalyze the hydroxylation of
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abundance of HIF-hydroxylases will determine HIF-α
accumulation and activity at distinct pO2's. Expression of
the PHD iso-enzymes varies between tissues but no specific
role for this difference has been determined in vivo [53].
PHD1 is highly expressed in the testis whereas PHD3
mRNA is abundant in the heart. A recent study using newly
developed monoclonal antibodies determined protein distri-
bution throughout several organs and revealed tissue specific
distribution and also differences in staining intensity
between normal and malignant tissue [54]. Knock-out mice
for PHD1 to 3 have been generated and are currently
characterized with respect to their phenotype. Homozygous
PHD2−/− mice are not viable, but PHD1−/− and PHD3−/−
are. An interesting phenotype was reported for PHD1−/−
mice which showed a significant protection from hypoxia
induced muscle damage in a hind limb ischemia model (P.
Carmeliet, Keystone Symposium January 2006, Brecken-
ridge, CO).
A strong stimulus that regulates PHD2 and PHD3
abundance is hypoxia itself. Initially it was observed that
the half-life of HIF-1α was significantly shortened after
prolonged or severe hypoxic periods [55]. It was found that
the pVHL/HIF pathway regulated hypoxic inducibility of
PHD2 and 3 [56] and recently functional HREs were isolated
and characterized in the promoter of the PHD2 gene [57] as
well as of the PHD3 gene [58]. In contrast, PHD1 is not
induced by hypoxia, potentially even reduced in a particular
subset of cells [59]. Several negative regulatory elements in
the PHD1 promoter, and a possible role for ARNT in this
hypoxic down-regulation, have been reported [60]. Like-
wise, levels of FIH-1 are not affected by hypoxia [61].
Hypoxic induction of PHD2 and 3 therefore forms a negative
feedback loop whose function is not yet entirely clear. It has
recently been suggested that higher levels of hydroxylase
expression may extend the regulatory range of the oxygen
sensors to more severe hypoxia [42]. On the other hand,
induction, notably of PHD3, appears to be of particular
importance for the reoxygenation phase when higher PHD3
levels may increase the dynamics of the hypoxic response by
shortening the half-life of HIF-1α protein. Very recently, two
alternatively processed PHD3 transcripts, designated
PHD3Δ1 and PHD3Δ4 were identified [62]. The expression
of both PHD3 and PHD3Δ1 was observed in all tissues and
cell lines tested, although the expression of the novel
PHD3Δ4 appeared to be restricted to primary cancer tissues.
The function of PHD3Δ4 was assessed in transfection
experiments showing a preserved prolyl hydroxylase activity
although the impact on O2 sensing remains to be fully
elucidated.
Another open question is whether the localization of
PHDs is affected after hypoxic induction. PHD enzymes
show a distinct intracellular distribution pattern with PHD1
mostly, if not exclusively, localized in the nucleus whereas
PHD2 predominantly resides in the cytoplasm and PHD3 is
found in both cellular compartments [61]. A recent studyusing novel antibodies more or less confirmed the localiza-
tion of PHD2 and 3 while PHD1 was also found in the
cytoplasm [54]. This may indicate that cell-specific differ-
ences exist or that particular circumstances affect the
translocation of the oxygen sensors. It has for example
been described that PHD1 is estrogen-dependent although no
effects on subcellular localization were studied so far [63].
Very recent work, however, provides evidence that cellular
localization is a dynamic process, particularly that PHD2
may also be found in the nucleus upon induction [64].
Irrespective of the cellular localization and the tissue
distribution, the current consensus is that PHD2 is the
main enzyme that regulates steady state levels of HIF-1α.
This is indicated by the fact that knock-down of PHD2 by
siRNA is sufficient to increase HIF-1α levels under
normoxic condition [65]. In addition, HIF target genes
were up-regulated indicating that inhibition of PHD2 alone is
sufficient for HIF-1 target gene activation although FIH-1
activity was not reduced. This notion has further been tested
in a study where the relative importance of PHD2 at different
levels of hypoxia was found to be most important for
normoxic and moderately hypoxic situations whereas FIH-1
appears to regulate HIF activity at more severe hypoxia [49].
This fits in fact the lower Km value for oxygen of FIH-1 as
mentioned above.
Most probably, however, regulation of PHDs comprises
several more levels of complexity. PHD activity is inhibited
when intracellular calcium is chelated although no obvious
calcium binding site has been identified [66]. This could
indicate that other calcium dependent cofactors are required
for full PHD activity. The ring finger E3-ubiquitin ligases
Siah1a/2 were recognized to co-immunoprecipitate with
PHD1 and 3 [67]. Siah1a/2 appear to particularly affect
PHD3 levels by increased proteolysis. Siah1a/2-deficient
cells showed higher levels of PHD3 and a loss of hypoxic
HIF-1α induction which could be reversed by siRNA against
PHD3. Interestingly, Siah proteins themselves are hypoxia-
inducible suggesting that, under hypoxic conditions, PHD3
proteolysis will increase. On the other hand, PHD3 is HIF-
1α target gene and PHD3 expression is induced in hypoxia
[58,61]. Thus hypoxia increases expression and degradation
of PHD3 which in turn controls HIF-1α levels. How this
intricate regulation and counter-regulation affects physio-
logical oxygen sensing is unclear at present although
Siah2−/− mice subjected to hypoxia displayed an impaired
erythropoietic response which might indicate physiological
relevance of this regulation [67].
When the initial biochemical purification of an HIF-1
prolyl hydroxylase revealed a 320–440 kDa complex that
appeared much larger in mass than individual PHDs [68], it
became obvious that other proteins associate with PHDs. In
an attempt to characterize such proteins, the chaperonin
complex TriC (aka CCT) was found to co-purify with PHD3.
Whether PHD3 represents a folding substrate for TriC is
currently not clear [69]. Interaction of PHD2 with OS-9, a
widely expressed protein of yet unassigned function, appears
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HIF-1α [70]. Knock-down of OS-9 by siRNA increased
HIF-1α protein levels, HIF-1-mediated transcription, and
expression of the HIF-1 target gene VEGF under non-
hypoxic conditions. Interaction of the tumor suppressor
protein ING4 with PHD2 surprisingly did not affect either
PHD2 activity or HIF stability [71]. Instead, ING4 binding to
PHD2 appears to interfere with transcriptional activation of
HIF-1α either by interacting with the TAD-N domain within
the ODD or through hindrance of the correct folding of the
active HIF complex between the C-terminus and the DNA
binding domains [71]. This field is now under active
investigation, particularly with respect to other PHD targets
[72]. In this regard, the groups of R. Wenger and D.
Katschinski recently reported several yeast-two-hybrid
based identifications of novel PHD1 (i.e. onconeural
cerebellar degeneration-related protein 2, Cdr2), PHD2 (i.e.
peptidyl-prolyl cis/trans isomerase FK506-binding protein
38, FKBP38) and PHD3 (i.e. activating transcription factor-
4, ATF-4) interacting factors that might either represent PHD
hydroxylation targets (Cdr2, ATF-4) or PHD activity
modulators (FKBP38) (see Acta Physiol. 2006, vol. 186,
suppl. 1, PM07P-4, PM08A-5, PM08A-7). Moreover, the
novel WD-repeat protein Morg1 was identified to act as a
molecular scaffold for PHD3 [73]. Morg1 was shown to
support the specific activity of PHD3 and may even be
important for maximal activity of the enzyme under certain
conditions.
4. Effect of divalent metal ions on PHD activity
Classically it had been reported that cobalt chloride can
mimic the anemic or hypoxic induction of erythropoietin
production and in fact cobalt chloride was used as an
erythropoietic agent [74]. Later, in vivo and in vitro studies
revealed that this effect is due to cobalt chloride dependent
induction of HIF-1 [46]. Since nickel (Ni2+) and manganese
(Mn2+) acted in a similar way and induced erythropoietin
production it was initially proposed that those divalent
transition metal ions would replace iron in the potential heme
protein sensor, thereby locking this protein in its active
deoxy conformation [31]. This concept has been perpetuated
when the Fe2+-dependent PHD enzymes were identified as
O2 sensors and is currently used to explain why divalent
metal ions increase HIF-1α protein, even though PHDs
turned out to be non-heme binding dioxygenases (i.e. iron is
directly coordinated with the protein). It has indeed been
found that hypoxia mimetics like Co2+ and iron chelators
inhibit PHD activity [12]. However, a competing hypothesis
has been proposed, whereby cobalt and nickel deplete
intracellular ascorbate, which is also required for full
enzymatic activity (see below; [75]). Nevertheless, the
absolute requirement of Fe2+ for HIF hydroxylase activity
is beyond doubt. When recombinant PHD enzymes were
recently purified and tested for their Km values it was found
that iron was so tightly bound to these enzymes that Kmvalues for iron could only be estimated with lower than
0.1 μM [76]. For FIH-1, a Km for iron of 0.5 μM was
measured, which still is considerably lower than the Km of
2 μM for C-P4H1. Although the values for PHDs were only
estimated, high affinity binding of the metal by PHDs is
supported by the finding that, in vitro, the iron chelator
desferrioxamine (DFO) and the divalent metal ions (Co2+,
Ni2+, Mn2+) were more effective in inhibiting FIH-1 than
PHD preparations (see Fig. 1). However, the obvious and
important question whether cellular iron availability affects
physiological hydroxylase function has not yet been fully
addressed. One recent report found changes in iron
distribution in response to NO treatment and may thus
indicate that cellular iron distribution is in fact able to affect
oxygen sensing [77]. Although the direct addition of iron to
cultures reduced HIF-1α levels, it may be doubted whether
this iron is in fact transferred to the PHD without prior
oxidation and may thus affect other yet unknown ways of
HIF-α accumulation [78].
5. Substrate specificity, ascorbate requirement and ROS
Both in HIF-1α and HIF-2α the proline residues to be
hydroxylated are in the context of an LXXLAP consensus
sequence. This sequence is not recognized by C-P4H1, but
by PHDs. Within this consensus are the two critical proline
residues 402 and 564 in human HIF-1α which are both
recognized by PHD1 and 2 [79], but not by PHD3. PHD3
will only hydroxylate proline 564. In addition, Leu574 in
human HIF-1α was found to be essential for pVHL binding
[80] and PHD2 recruitment to the Pro564 hydroxylation site
[81]. High substrate specificity of PHDs to recognize these
particular proline residues, therefore, results from the
conserved presence of the LXXLAP consensus together
with adjacent ‘recruiter residues’. Consequently, the Km for
19 aa model peptides including the consensus sequence was
as low as 7 to 8 μM [39]. Despite this high substrate
specificity, in vitro mutagenesis studies unexpectedly
revealed that prolyl hydroxylation is rather tolerant towards
a range of substitutions in the vicinity of the target proline
[79]. It has been reasoned that these effects may be due to
high concentration of short peptides used for in vitro studies.
Therefore X-ray structure studies of PHDs and HIF-α
protein substrate are mostly needed. This was so far only
achieved for FIH-1 bound to the TAD-C of HIF [45]. Here
the higher stringency and particularly the requirement for
valine 802 for hydroxylation activity became obvious when
an extensive set of hydrogen bonds of the TAD-C was found
to be formed with FIH-1 to bring the asparagine 803 close to
the catalytic iron of the active site of the enzyme [45].
Moreover, structural changes have been observed between a
state where the TAD-C is bound to FIH-1, which would
cause hydroxylation and inhibition of activation, and an
active state where p300 is bound to the TAD-C [82,83].
Collectively, recognition of the substrate, both by PHDs and
FIH-1, appears to depend on multiple residues within the
648 J. Fandrey et al. / Cardiovascular Research 71 (2006) 642–651surrounding protein which ensure highly specific substrate
recognition.
Ascorbate has been proposed to protect prolyl hydroxylases
from uncoupled reactions where no substrate is hydroxylated
and reactive oxygen species (ROS) may be generated that
could damage the enzymes [41]. In fact, ascorbate deficiency
has been found to be limiting for PHD function in human
tumor cells causing highHIF-1α levels [78]. Usually C-4PH1
enzymes catalyze the uncoupled decarboxylation of 2OG at a
rate of less than 1% of the complete reaction [41]. When
proline is hydroxylated, a number of cycles can be run
without ascorbate, but then Fe3+ needs to be reduced for
continued activity of the enzyme. In the case of uncoupled
reactions, e.g. if no available substrate is recognized,
ascorbate may act as an alternative O2 acceptor to limit the
generation of reactive oxygen species. Under these condi-
tions, ascorbate is consumed stoichiometrically. For other
2OG-dependent oxygenases the generation of ROS has been
described and can inactivate the related oxygenases by self-
oxidation which might cause fragmentation of the enzymes
[84]. So far, uncoupling has not been observed for PHDs, but
about 1% of the maximum activity of FIH-1 did not account
for hydroxylation in the presence of an HIF substrate [40].
While a great percentage of uncoupled reactions may be
harmful to the enzymes and potentially other targets in the
cell as pointed out above, the precise mechanism is not fully
elucidated. One particular open question is whether the HIFα
substrate binds prior to or after oxygen has been bound to the
enzyme. On the one hand, only substrate-bound protein
would bind oxygen and thus substrate recognition would
indeed reduce the potential for ROS generation. On the other
side, oxygen affinity may well be modulated by substrate
binding as pointed out above [37]. Another under-investi-
gated issue concerns our limited understanding when
comparing the regulation of HIF-hydroxylase activities
between organisms capable of de novo ascorbate synthesis
(e.g. rodents) and others for which vitamin C is an essential
nutrient (e.g. humans, primates, guinea pigs).
With respect to ROS it is noteworthy that the model of
cellular oxygen sensing by oxygen-dependent enzymatic
activity of PHDs is in competition with the hypothesis that
mitochondria and/or other cellular oxidases generate ROS to
control oxygen dependent gene expression [85]. Reduced
levels of ROS, particularly H2O2, have been observed under
hypoxia and were correlated with increased HIF-dependent
erythropoietin expression [86]. This was later associated
with a perinuclear Fenton type reaction that reduced HIF-1α
levels and would thus indicate that locally increased ROS
diminish HIF activation [87]. On the other hand, ROS have
been found to inhibit PHD activity which would explain how
ROS can increase HIF-1α levels [88]. Increased ROS
production by mitochondria, however, has often been
achieved by the use of inhibitors of mitochondrial respiration
which have recently been shown to completely alter cellular
oxygen supply [89]. Due to diffusion limited oxygen
availability to cells in culture [51], any inhibition of oxygenconsumption would significantly alter pericellular oxygen
tensions. As such, it has recently been proposed that
inhibition of the mitochondrial electron transport chain
would not necessarily produce reactive species that act as
signaling molecules, but could instead increase oxygen
availability for PHD enzymes [89]. So far, it has not been
possible to clearly define intracellular O2 levels and,
particularly, O2 gradients that occur with lowest values
around mitochondria where oxygen is consumed. However,
an interesting scenario has been proposed for the action of
nitric oxide (NO) with respect to inhibition of HIF
accumulation under hypoxic conditions. NO is known to
inhibit mitochondrial O2 consumption. Under the influence
of NO, oxygen, which is no longer consumed by the
mitochondria, may be redistributed to PHD enzymes causing
increased activity and thus HIF-1α degradation [90]. Similar
mechanisms may account for inhibition of HIF-α accumu-
lation under the influence of inhibitors of mitochondrial
respiration or depletion of mitochondrial DNA (ρ0 cells).
This would not require the action of ROS for oxygen sensing
and will explain results that were recently reported to
substantiate this hypothesis [91,92]. Although a direct effect
of ROS on Fe2+ in PHD enzymes was claimed [88], this
finding contradicts the observation that upon reoxygenation
where, without doubt, major amounts of ROS are produced,
rapid degradation of HIF-α due to PHD activity is not
impaired.
6. Linking oxygen sensing with tricarboxylic acid cycle
activity
Recently some exciting reports on the effects of
tricarboxylic acid cycle (TCA) intermediates affecting
PHD activity have been published [93–95]. Since PHDs
are 2OG-dependent enzymes and since 2OG is an interme-
diate in the TCA, an obvious follow-up question is: Does
cross-talk between these two important cellular systems
affect oxygen sensing capacity? While the Km values for
2OG of PHDs are in the range of 55–60 μM, and for FIH–1
around 25 μM [39,40], the exact 2OG concentration within
the cell or even in a subcellular compartment is difficult to
calculate. It was therefore important to dissect that hereditary
cancer syndromes associated with defects in succinate
dehydrogenase (subunits B, C or D) displayed competitive
inhibition of PHD activity through increased levels of
succinate [93]. While this would biochemically be referred to
as product inhibition, another hereditary cancer syndrome
where fumarate hydratase is deficient, revealed that
increased fumarate levels are likewise able to significantly
inhibit 2OG-dependent PHD activity and thus increase HIF-
1α levels [94]. In addition, in an earlier study where the role
of co-substrates for prolyl hydroxylases was investigated, it
was found that the endogenous 2-oxoacids pyruvate and
oxaloacetate can both act as competitive inhibitors of 2OG-
dependent oxygenases [96]. More recently, pyruvate and
oxaloacetate have also been found to induce HIF-1 [97]. In
649J. Fandrey et al. / Cardiovascular Research 71 (2006) 642–651summary, the effect of intermediates of the citric acid cycle
(TCA intermediates, see Fig. 1) on oxygen sensing provides
an explanation for the pathology observed with defects in
these hereditary cancer syndromes. Whether this cross-talk is
also found under physiological circumstances will be an
interesting field of investigation.
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